L. Sandman et al., INACTIVATED HEPATITIS-A VACCINE - A SAFETY AND IMMUNOGENICITY STUDY IN HEALTH-PROFESSIONALS, The Journal of infectious diseases, 171, 1995, pp. 50-52
The safety and immunogenicity of an inactivated hepatitis A vaccine (H
M175) were evaluated in 151 seronegative health professionals (age ran
ge, 21-65 years; mean, 30). A 720-ELISA unit dose was administered to
78 vaccinees at 0, 1, and 6 months and to 73 vaccinees at 0, 1, and 12
months. Seroconversion rates were 90% in both groups 1 month after th
e first inoculation and 99% and 100%, respectively, 1 month after the
second inoculation. Geometric mean antibody titers (GMTs) 1 month afte
r the third inoculation were highest in the group vaccinated at 0, 1,
and 12 months. GMTs were higher in women than in men. The vaccine was
well tolerated; the most frequent side effect was transient soreness a
t the site of inoculation. No serious adverse reactions were observed.
Thus, HM175 inactivated hepatitis A vaccine is safe and highly immuno
genic.